(Q34821078)

4 August 2017

1 reference

title

Thyroid cancer: burden of illness and management of disease (English)

1 reference

4 August 2017

1 reference

Rebecca L Brown

1

1 reference

4 August 2017

Jonas A de Souza

series ordinal

2

1 reference

4 August 2017

Ezra Ew Cohen

series ordinal

3

1 reference

4 August 2017

publication date

4 April 2011

1 reference

4 August 2017

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

page(s)

193-199

1 reference

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Phase II trial of sorafenib in metastatic thyroid cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Epidemiology of thyroid nodules

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Motesanib diphosphate in progressive differentiated thyroid cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Total thyroidectomy for differentiated thyroid cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Thyroid-hormone therapy and thyroid cancer: a reassessment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Papillary thyroid carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Geographic pathology of occult thyroid carcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

BRAF is a therapeutic target in aggressive thyroid carcinoma.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Natural history, treatment, and course of papillary thyroid carcinoma

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079916

Does the method of management of papillary thyroid carcinoma make a difference in outcome?

26 October 2018

1 reference

12 December 2020

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

12 December 2020

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma

1 reference

12 December 2020

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

1 reference

12 December 2020

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

1 reference

12 December 2020

Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake

1 reference

12 December 2020

Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma

1 reference

12 December 2020

Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective

1 reference

12 December 2020

Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients

1 reference

12 December 2020

Identifiers

DOI

10.7150/JCA.2.193

1 reference

release_m5ufzruu2bgbtgvirggebyrwfu

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m5ufzruu2bgbtgvirggebyrwfu

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3079916

1 reference

4 August 2017

1 reference